CN102579878B - 红芦籽颗粒及其制备方法和应用 - Google Patents
红芦籽颗粒及其制备方法和应用 Download PDFInfo
- Publication number
- CN102579878B CN102579878B CN201210061334.0A CN201210061334A CN102579878B CN 102579878 B CN102579878 B CN 102579878B CN 201210061334 A CN201210061334 A CN 201210061334A CN 102579878 B CN102579878 B CN 102579878B
- Authority
- CN
- China
- Prior art keywords
- extract
- dauci sativae
- radix dauci
- rhizoma phragmitis
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 42
- 235000014676 Phragmites communis Nutrition 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 83
- 201000005569 Gout Diseases 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000007779 soft material Substances 0.000 claims abstract description 7
- 239000001387 apium graveolens Substances 0.000 claims description 29
- 240000007087 Apium graveolens Species 0.000 claims description 24
- 235000002764 Apium graveolens Nutrition 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 3
- 235000007319 Avena orientalis Nutrition 0.000 claims description 2
- 244000075850 Avena orientalis Species 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000004137 mechanical activation Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000002961 anti-hyperuricemic effect Effects 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 18
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 17
- 229940116269 uric acid Drugs 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 12
- 241000196324 Embryophyta Species 0.000 abstract description 8
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000008021 deposition Effects 0.000 abstract description 4
- 239000000419 plant extract Substances 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000001556 apium graveolens l. seed extract Substances 0.000 abstract 2
- 229940008396 carrot extract Drugs 0.000 abstract 2
- 229940116732 celery seed extract Drugs 0.000 abstract 2
- 235000013312 flour Nutrition 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 238000007580 dry-mixing Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 16
- 108010093894 Xanthine oxidase Proteins 0.000 description 11
- 102100033220 Xanthine oxidase Human genes 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 229940075420 xanthine Drugs 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 6
- 229960005101 febuxostat Drugs 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010046337 Urate nephropathy Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000387 litholytic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种红芦籽颗粒,由纯天然植物食品燕麦粉,从植物中提取的鲜芦根提取物,红萝卜提取物和芹菜籽提取物组成。将上述各组分分别过60目筛,先将鲜芦根提取物、红萝卜提取物、燕麦粉干混,加80%乙醇溶液适量制备软材,过筛制粒,烘干、整粒,加入芹菜籽提取物混匀,分装成袋即得。本发明的红芦籽颗粒,可明显提高人体从尿中排除尿酸的能力,降低尿酸在体内的沉积,从而化解结石、控制痛风复发可在制备防治痛风和高尿血酸症药物中的应用。本发明采用纯天然植物食品及植物提取物为原料,配方独特,配比合理,原料易得,使用方便,疗效好,安全卫生,价格适宜,成本较低,具有广阔的市场前景。
Description
技术领域
本发明属制药领域,涉及红芦籽颗粒及其制备方法和应用。该红芦籽颗粒对于痛风和高尿血酸症患者,可以有效抑制黄嘌呤氧化酶的活性,降低尿酸;对于未患痛风但尿酸值偏高的人,可以预防痛风。
背景技术
近年来由于饮食结构改变,高蛋白质和高嘌呤食物摄取增加,我国的高尿酸血症和痛风患者日渐增多,有直追西方国家甚至超越之势。
黄嘌呤氧化酶催化次黄嘌呤转化成黄嘌呤从而最终生成尿酸,尿酸生成过多和(或)其代谢障碍都会导致高尿酸血症的产生,而高尿酸血症是痛风发病的生化学基础,也是形成痛风的关键病因,血中生成尿酸过多或排泄过少,抑或其它因素均能导致高尿酸血症。尿酸一旦超出正常值,便会形成尿酸盐,继而随血流达到下肢远端形成沉积,导致痛风。严重者会造成关节活动障碍或畸形,临床上称为痛风性关节炎。人体尿酸的正常值为150-420μmol/L,过多的尿酸会在肾脏沉积后形成尿酸性肾结石及肾实质损害,临床上称为尿酸性肾病,又叫痛风性肾病,可引起肾绞痛发作、血尿、肾盂积水及肾功能损害,严重者可发生肾功能衰竭及尿毒症,是导致痛风病人死亡的主要原因之一。
在最近50年内,痛风病治疗领域新品匮乏,现有药物都存在对患者的肠胃道刺激和损伤大的缺陷。目前痛风和高尿酸血症的治疗主要使用抗炎药来缓解该疾病的红、胖、热、痛等症状,并在疾病发展不同阶段上选择排尿酸药物或黄嘌呤氧化酶抑制剂以缓解高尿酸血症,控制病情发展。
燕麦粉不含胆固醇,带有全谷物类的少量脂肪。富含可溶性纤维。富含维生素B群(尤其是维生素B1、B2以及菸碱酸)、维生素C、E以及叶酸。并且含有丰富的钙、磷、铁、铜、锌、锰、矽。燕麦亦含有丰富的水溶性纤维、β-聚葡萄糖以及植物碱、植物皂素。
鲜芦根性寒,味甘,有利尿解毒的作用。芦根能溶石,适宜于尿酸性疾患及痛风者食用。在古方中多用鲜品。将鲜芦根捣烂绞汁入药者,称鲜芦根汁,亦称芦根汁。养阴生津之力更强,解毒之效更速,尤其适用于热病烦渴,呕吐;胃弱而难进药食之幼儿及中毒急症者。据现代研究结果证明,芦根中含有大量维生素B1、B2和维生素C,惟以鲜品或鲜汁入药者可保持维生素含量损失最小。
红萝卜属碱性食品,是一种基本上不含嘌呤的蔬菜,具有降低血脂、胆固醇、稳定血压的作用,红萝卜中含有丰富的活性酶,生食可有效的促进嘌呤的代谢,红萝卜中还含有大量的钾、磷、钙、铁、维生素K、Vc等物质,这样就可以有效地提高血液质量、碱化血液并有利尿、溶石作用。此外,红萝卜富含钾,为其他萝卜的几倍甚至几十倍。众所周知钾可以调节细胞内适宜的渗透压和体液的酸碱平衡,参于细胞内糖和蛋白质的代谢,这对痛风患者血尿酸值的调节十分有利。
芹菜籽所含降压、降脂成分是芹菜的50倍,短期服用起到降血压,降血脂的作用,长期服用远远优于其他中西药品,无任何毒副作用。芹菜籽对高血压有特效。有降血压、降血脂的作用。芹菜籽对风温症、风湿关节炎、痛风、高尿酸症等都有舒解作用。
发明内容
本发明的目的是提供一种红芦籽颗粒,其组分包括纯天然植物食品燕麦粉,从植物中提取的鲜芦根提取物,红萝卜提取物和芹菜籽提取物。
上述红芦籽颗粒,各组分的重量配比为燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物为26.1~31.9:9.9~10.1:0.9~1.1:1.8~2.2,其中配比优选为燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物为29:10:1:2。
本发明的另一个目的在于提供了红芦籽颗粒的制备方法:将上述各组分分别过60目筛,备用,按配方量称取预处理过的原料,将鲜芦根提取物、红萝卜提取物、燕麦粉干混10~15分钟,加80%乙醇溶液适量制备软材;经12~16目筛制粒;于50℃~55℃烘干;整粒;加入芹菜籽提取物作为香精;混匀;分装成袋;即得。
本发明的再一个目的是提供上述制得的红芦籽颗粒在制备防治痛风和高尿血酸症药物中的应用,其服用方法为:一天两袋,早晚各一袋,服用时用热开水冲泡饮用。
在正常情况下,人体从尿中排除尿酸的能力为总尿酸值的5%左右;如果服用本发明的红芦籽颗粒,排除尿酸的量就可明显提高,降低尿酸在体内的沉积,从而化解结石、控制痛风复发。
本发明的红芦籽颗粒在血液中尿酸高的人群中经过实际服用,已证明其效果明显,可以防治痛风疾病。
本发明采用纯天然植物食品及植物提取物为原料,配方独特,配比合理,原料易得,使用方便,疗效好,安全卫生,价格适宜,成本较低,具有广阔的市场前景。
具体实施方式
本发明结合实施例作进一步的说明。以下实施例对本发明进行描述,这些例子仅仅是为了说明而不能理解为对本发明范围的限制。
下面的实施例中,使用的燕麦粉、鲜芦根提取物、红萝卜提取物和芹菜籽提取物按以下方法制得:
燕麦粉的制备方法为:将裸燕麦去皮、脱茸毛,85℃进行烘培4小时,之后通过机械粉碎,检验,蒸汽灭菌,即得。
鲜芦根提取物的制备方法为:将鲜芦根粉碎,用10倍量水80℃提取2次,2h/次,提取液减压浓缩,喷雾干燥,粉碎,过筛,即得。
红萝卜提取物的制备方法为:将红萝卜粉碎,用水80℃提取3次,第一次10倍量水提取2h;第二次8倍量水提取1.5h;第三次6倍量水提取1.0h,过滤,浓缩,喷雾干燥,粉碎,过筛,即得。
芹菜籽提取物的制备方法为: 芹菜籽用10倍量水80℃提取2次,2h/次,提取液减压浓缩,喷雾干燥,粉碎,过筛,即得。
实施例1 (燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物重量比为29:10:1:2)
将燕麦粉 2900克,鲜芦根提取物1000克,红萝卜提取物100克,芹菜籽提取物200克分别过60目筛,备用。将过筛后的原料:鲜芦根提取物1000克、红萝卜提取物100克、燕麦粉2900克干混10~15分钟,加80%乙醇溶液适量制备软材;经12~16目筛制粒;于50℃~55℃烘干;整粒;再加入过筛后的芹菜籽提取物200克;混匀;分装成袋,每袋装4.2克干燥的颗粒,共1000袋;即得。
实施例2 (燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物重量比为27:9:1.1:2)
将燕麦粉2700克,鲜芦根提取物900克,红萝卜提取物110克,芹菜籽提取物200克分别过60目筛,备用。将过筛后的原料:鲜芦根提取物900克、红萝卜提取物110克、燕麦粉2700克干混10~15分钟,加80%乙醇溶液适量制备软材;经12~16目筛制粒;于50℃~55℃烘干;整粒;再加入过筛后的芹菜籽提取物200克;混匀;分装成袋,每袋装3.91克干燥的颗粒,共1000袋;即得。
实施例3 (燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物重量比为28:10:0.9:1.9)
将燕麦粉2800克,鲜芦根提取物1000克,红萝卜提取物90克,芹菜籽提取物190克分别过60目筛,备用。将过筛后的原料:鲜芦根提取物1000克、红萝卜提取物90克、燕麦粉2800克干混10~15分钟,加80%乙醇溶液适量制备软材;经12~16目筛制粒;于50℃~55℃烘干;整粒;再加入过筛后的芹菜籽提取物190克;混匀;分装成袋,每袋装4.08克干燥的颗粒,共1000袋;即得。
实施例4 (燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物重量比为30:9.5:1:1.8)
将燕麦粉 3000克,鲜芦根提取物950克,红萝卜提取物100克,芹菜籽提取物180克分别过60目筛,备用。将过筛后的原料:鲜芦根提取物950克、红萝卜提取物100克、燕麦粉3000克干混10~15分钟,加80%乙醇溶液适量制备软材;经12~16目筛制粒;于50℃~55℃烘干;整粒;再加入过筛后的芹菜籽提取物180克;混匀;分装成袋,每袋装4.23克干燥的颗粒,共1000袋;即得。
实施例5 检测本发明红芦籽颗粒的生物活性
以下对实施例1-4所制得的红芦籽颗粒的生物活性,即对黄嘌呤氧化酶的抑制作用进行了测试。实验如下:
A、实验材料:
黄嘌呤,黄嘌呤氧化酶,Na2HPO4.12H2O(AR),NaH2PO4·2H2O(AR),实施例1所制得的红芦籽颗粒,非布索坦(分子量316)。
B、实验步骤:
1)0.2M PH7.5磷酸盐缓冲液的配制(PBS)
称取Na2HPO4.12H2O 15.6g(或 NaH2PO4·2H2O 13.8g)加重蒸水至500ml溶解,取16ml 0.2mol/L的 NaH2PO4和160ml 0.2mol/L的Na2HPO4.12H2O,充分混合即为0.2mol/L的PBS。
2)黄嘌呤溶液的配制
取黄嘌呤适量,加上述磷酸盐缓冲液稀释至75Mm/L。静置15min。
3)供试品溶液的配制
取实施例1-4所制得的红芦籽颗粒样品各约0.3g+水/DMSO溶液20ml,超声加热使溶解或混旋,10000r/min离心,取上清液。取非布索坦(对比物)约26mg加DMSO2ml加热溶解,10000r/min离心,取上清液。
4)黄嘌呤氧化酶的配制
取黄嘌呤氧化酶适量加上述磷酸缓冲液配置成约0.009U/ml。
5)加样及分组
空白管:加入黄嘌呤3ml,测A值,加入DMSO 20ul,涡旋混匀测A值。
模型管:加入黄嘌呤3ml,测A值,加入DMSO 20ul,涡旋混匀测A值。
对照管:加入黄嘌呤3ml,测A值,加入20ul 红芦颗粒,涡旋混匀测A值。
样品管:加入黄嘌呤3ml,测A值,加入20ul 非布索坦,涡旋混匀测A值。
以上各管加样混匀后,即刻放入37℃水浴环境中,20min后。
6)酶解及检测
以上除空白管外,各管均加入50ul黄嘌呤氧化酶,37℃孵育30min。然后以0.2M PH7.5磷酸盐缓冲液调零,在270nm下,测定各个试验管吸光度变化,并比较酶抑制率差异。
计算公式:
抑制率(%)=(模型差值平均值-样品差值平均值)/模型差值平均值*100
表1列举了实施例1-4所制得的红芦籽颗粒样品在对黄嘌呤氧化酶抑制检测中所得的数据,本实验中以非布索坦作为对比物。
表-2 是实施例1-4所制得的红芦籽颗粒对黄嘌呤氧化酶抑制作用的检测。
从表中数据可以得出,实施例1-4所制得的红芦籽颗粒和非布索坦均能抑制黄嘌呤氧化酶的活性,其中实施例1(优选配比)制得的红芦籽颗粒对黄嘌呤氧化酶的抑制率最高,和非布索坦一样均为100%。
Claims (3)
1.一种红芦籽颗粒,由燕麦粉、鲜芦根提取物、红萝卜提取物和芹菜籽提取物制成,各组分的重量配比为燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物为26.1~31.9:9.9~10.1:0.9~1.1:1.8~2.2;其中燕麦粉的制备方法为:将裸燕麦去皮、脱茸毛,85℃进行烘培4小时,之后通过机械粉碎,检验,蒸汽灭菌,即得;鲜芦根提取物的制备方法为:将鲜芦根粉碎,用10倍量水80℃提取2次,2h/次,提取液减压浓缩,喷雾干燥,粉碎,过筛,即得;红萝卜提取物的制备方法为:将红萝卜粉碎,用水80℃提取3次,第一次10倍量水提取2h;第二次8倍量水提取1.5h;第三次6倍量水提取1.0h,过滤,浓缩,喷雾干燥,粉碎,过筛,即得;芹菜籽提取物的制备方法为: 芹菜籽用10倍量水80℃提取2次,2h/次,提取液减压浓缩,喷雾干燥,粉碎,过筛,即得;
所述红芦籽颗粒通过以下步骤制备:将燕麦粉、鲜芦根提取物、红萝卜提取物和芹菜籽提取物分别过60目筛,备用,按重量配比称取预处理过的原料,将鲜芦根提取物、红萝卜提取物、燕麦粉干混10~15分钟,加80%乙醇溶液适量制备软材,经12~16目筛制粒,于50℃~55℃烘干,整粒,加入芹菜籽提取物,混匀,分装成袋,即得。
2.根据权利要求1所述的一种红芦籽颗粒,其特征在于,各组分的重量配比为燕麦粉:鲜芦根提取物:红萝卜提取物:芹菜籽提取物为29:10:1:2。
3.根据权利要求1所述的一种红芦籽颗粒在制备防治痛风和高尿酸血症药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210061334.0A CN102579878B (zh) | 2012-03-09 | 2012-03-09 | 红芦籽颗粒及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210061334.0A CN102579878B (zh) | 2012-03-09 | 2012-03-09 | 红芦籽颗粒及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102579878A CN102579878A (zh) | 2012-07-18 |
CN102579878B true CN102579878B (zh) | 2014-03-26 |
Family
ID=46469479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210061334.0A Active CN102579878B (zh) | 2012-03-09 | 2012-03-09 | 红芦籽颗粒及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102579878B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103181595B (zh) * | 2013-04-03 | 2014-04-02 | 刘银松 | 一种可降低尿酸的红萝卜汁保健饮料 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY124001A (en) * | 1999-04-23 | 2006-06-30 | E Excel Int | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
CN101322552B (zh) * | 2007-06-11 | 2012-06-27 | 刘金忠 | 一种调节血糖的膳食配方及其加工工艺 |
CN101810336B (zh) * | 2010-04-30 | 2012-03-21 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
-
2012
- 2012-03-09 CN CN201210061334.0A patent/CN102579878B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102579878A (zh) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101606704B (zh) | 一种具有多种功能作用的膳食纤维食品 | |
AU2009252911B2 (en) | Composition comprising 1, 3 /1, 6 beta glucan for reducing weight | |
CN104856003A (zh) | 糖尿病非全营养配方食品 | |
CN106943423B (zh) | 具有调节肠道菌群结构作用的多糖组合物及其应用 | |
CN104855967A (zh) | 肥胖、减脂手术非全营养配方食品 | |
CN101467575A (zh) | 一种降糖调脂健身营养茶及其制作方法 | |
CN103829140A (zh) | 一种具有减肥及降血糖功能的谷物粉 | |
CN105495258A (zh) | 一种有助降尿酸的水果饮料 | |
CN104397538A (zh) | 一种减肥保健食品 | |
CN104783168A (zh) | 一种治疗腹泻的复配营养粉 | |
Syahrina et al. | Phytochemical screening and anti-hyperuricemia activity test in vivo of ethanolic extract of shallot (Allium cepa L.) skin | |
CN102579878B (zh) | 红芦籽颗粒及其制备方法和应用 | |
CN102657304A (zh) | 一种具有促进消化和缓解体力疲劳双功能的保健食品 | |
CN102266388A (zh) | 一种用于2型糖尿病及并发症预防和治疗的药物组合物 | |
KR20140016863A (ko) | 식물 재료의 항피로 조성물 및 이의 용도 및 제품 | |
CN101327000A (zh) | 竹笋壳提取物新用途 | |
CN102225198A (zh) | 一种抗肿瘤的药物组合物及其制备方法和应用 | |
CN110637909A (zh) | 一种用于治疗痛风的保健茶及其制备方法 | |
CN107441253A (zh) | 一种香椿花茶及其降糖效果的实验方法 | |
CN102614243A (zh) | 山茱萸总苷的提取方法及其在制备耐缺氧药物中的应用 | |
CN106822684A (zh) | 防治高尿酸血症的中药组合物、药物及其制备方法和应用 | |
CN112516262A (zh) | 一种缓解痛风的降酸茶及其制备方法 | |
CN106138900A (zh) | 辅助治疗高血糖和糖尿病并发症的组合物及其应用 | |
KR101391647B1 (ko) | 항비만 조성물 | |
CN105851336A (zh) | 铁皮石斛茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |